Yesterday the TGA released a notice of interim decision regarding the scheduling of CBD. The interim decision proposes that low-dose CBD products be classified under a new Schedule 3 entry, making these products available to Australian patients in consultation with their pharmacist, without a doctor’s prescription.
This sounds like great news for Auscann and Australians.
Yesterday the TGA released a notice of interim decision...
Add to My Watchlist
What is My Watchlist?